Abstract Prizes 2009

[f]Abstract Prizes 2009[/f] [u][f]Clinical Research[/f][/u] J. Ardill, et al, Belfast, United Kingdom. Assessment of the sensitivity of circulating neurokinin A and chromogranin A to changing prognosis in patients with serotonin-producing endocrine tumors of the ileum and colon A. Astudillo, et al, Oviedo, Spain. Snail as epithelial-mesenchymal transition marker in neuroendocrine tumors of the lung [f]R. Bettini, et al, Verona, Italy. Non-functioning pancreatic endocrine tumors: Any correlation of tumor size with malignancy?[/f] P. Brown, et al, The Woodlands, TX, USA. LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome A. Falchetti, et al, Florence, Italy. Early identification of the MEN1-associated gastrinomas: Use of the secretin test in the experience of the Center for Hereditary Endocrine Tumors of Florence, Italy P. Ferolla, et al, Perugia, Italy. Prevalence and features of MEN1 in a large cohort of gastroenteropancreatic and thoracic NET: Data from a large multicentric Italian database L. Krolicki, et al, Warsaw, Poland. Clinical results of PRRT with 90Y-DOTA TATE and 90Y/177Lu-DOTATATE - what is better for therapy? T. Meyer, et al, London, United Kingdom. Chemotherapy with 5-Fluorouracil, cisplatin and streptozocin (FCiSt) for neuroendocrine tumors A. Rinke, et al, Marburg, Germany. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group [f]J. Strosberg, et al, Tampa, FL, USA. First line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide[/f] [u][f]Basic/Translational Research[/f][/u] A. Couvelard, et al, Clichy, France. Molecular predictors of response to chemotherapy in advanced/metastatic gastroenteropancreatic endocrine tumors [f]A. Kalhan, et al, Cardiff, United Kingdom. Adenosine A2 receptor signalling mediates chromogranin A secretion from neuroendocrine tumors[/f] [f]M. Mei, et al, Beijing, China. Dual expression of α-internexin in pancreatic endocrine tumors and its implications[/f] [center] *** [/center] [color=]Two other abstract authors, each who presented their work in poster format at the Granada conference, also received monetary awards for their work:[/color] [f]P. Szybinski, et al, Cracow, Poland[/f]: [k]Colorectal neuroendocrine tumors of the gastroenteropancreatic tract (GEP-NET) - minimal invasive surgery[/k] [k]Radio-guided surgery for the intraoperative detection of neuroendocrine tumors of the gastroenteropancreatic tract (GEP-NET)[/k] [f]V. Prasad, et al, Bad Berka, Germany[/f]: [k]Impact of Peptide Receptor Radionuclide Therapy using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on renal tubular function: Long-term follow-up Management of neuroendocrine tumors of the rectum (rNET) using Ga-68 somatostatin receptor PET/CT (SR-PET/CT) and Peptide Receptor Radionuclide Therapy (PRRT) Pancreatic neuroendocrine tumor (pNET): Survival benefits and efficacy of Peptide Receptor Radionuclide Therapy (PRRT) using Y-90/Lu-177 DOTA-TATE Peptide Receptor Radionuclide Therapy (PRRT) of neuroendocrine tumor patients with carcinoid heart disease[/k]